Coave Therapeutics and Théa Open Innovation sign exclusive licensing, codevelopment and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa.
©Eveon
Coave Therapeutics and Théa Open Innovation sign exclusive licensing, codevelopment and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa.
